ZBH — Zimmer Biomet Holdings, Inc.

The tape is mixed. Recent news is genuinely positive: Q2 2026 revenue of $2.177B beat expectations, adjusted EPS of $2.07 beat by $0.06, and full-year adjusted EPS guidance was raised. U.S. hip/robotics momentum and institutional accumulation support the stock, but China VBP, international price erosion, manufacturing ramp costs, and an analyst consensus biased toward Hold keep a lid on sentiment. The 1.87% daily drop at $99.48 suggests buyers are not chasing this aggressively.

Revenue is inflecting upward: YoY growth in 2024 was roughly 1-4%, then accelerated to 9.7% in Q3 2025, 10.9% in Q4 2025, and 9.3% in Q1 2026 before cooling to 4.8% in Q2 2026 (4.0% organic constant currency) on China/international weakness. Margins are the weak spot: TTM operating margin is about 15.7%, down modestly from a year earlier, with quarterly GAAP swings from 12.8% to 19.2% due to charges; gross margin is stable at ~69.9%. Free cash flow remains solid at ~$1.27B TTM. This is a real sales acceleration, not a one-quarter blip, but margin expansion has not followed yet.

Cheap on forward earnings and sales, fair on quality. The TTM GAAP P/E of 24.1x is inflated by amortization and charges; using guided adjusted EPS of $8.53, the forward P/E is only ~11.7x. Price/sales of 2.26x is well below the 5-year average of 3.2x, and price/book is 1.5x. The lowish ROIC (5.5%) and net margin (9.5%) justify some discount, but the valuation is not demanding for a 70% gross margin, cash-generative medtech with a 1.06% dividend.

At $99.48, the market is paying ~11.7x forward adjusted EPS, which prices ZBH as a slow, ex-growth device maker with no margin upside. If robotics/hip share gains continue and Costa Rica/India manufacturing ramps drive operating leverage, earnings power supports $110-plus. If China price cuts and competition keep margins flat, the stock is roughly fairly valued around $100. This is a show-me re-rating story: estimates have already moved up, but the multiple will only expand when operating margin starts moving in the right direction.

As of 2026-08-27, the technicals are constructive but not stretched: RSI(14) is 55.8, price is 0.9% above the 20-day SMA, 6.3% above the 50-day SMA, and 9.2% above the 200-day SMA, while sitting ~7% below the 52-week high. That describes a quiet uptrend/range, not overbought momentum. A pullback toward the 50-day near $93-94 would be a better entry; a close above $106.88 would signal a real breakout.

• Interest rates and defensive rotation: low beta (~0.46) and a 1.06% dividend make ZBH an income/defensive play; falling rates would likely support the multiple.
• China volume-based procurement and Asia-Pacific price erosion are capping growth and pressuring gross margins.
• Elective procedure volume trends: aging demographics support long-term demand, but a macro slowdown can cause patients to defer joint replacements.
• Large-cap medtech has lagged the S&P 500 over the past year, leaving value investors hunting for cheap, cash-generative devices names.
• Hospital capital spending and reimbursement/regulatory uncertainty affect robotics and premium implant adoption.

• Q3 2026 earnings on November 4, 2026: another beat/raise would confirm the inflection and may finally force a re-rating.
• Continued adoption of ROSA robotics and U.S. hip/knee share gains, plus Paragon 28-driven trauma/foot & ankle growth.
• Operating margin inflection as Costa Rica and India plants scale and China pricing stabilizes.
• Capital deployment through debt paydown, buybacks, or dividend increases, since FCF remains robust at ~$1.27B TTM.

• China VBP and broader international price erosion intensifying, keeping organic growth below reported levels.
• Operating margin and ROIC staying depressed while manufacturing ramp costs and sales force transformation drag.
• Competitive pressure from Stryker, J&J, and Smith+Nephew in hips, knees, and robotics.
• Macro-led deferral of elective procedures, which would hurt the volume recovery.
• GAAP EPS remains burdened by amortization/charges, which could keep some value investors skeptical despite strong adjusted earnings.

ZBH is a reasonably priced, cash-generative medtech with an improving sales narrative but subpar margins and mediocre ROIC. The Q2 beat and guidance raise reduce downside risk, and the ~11.7x forward adjusted P/E plus $1.27B TTM FCF make it a credible value/income holding. I would not chase it at $99.48; a better risk/reward entry is near the $93-95 support zone or after Q3 confirms margin progress.

Applied a 12.75x forward multiple to FY2026 adjusted EPS midpoint of $8.53, yielding $108.76; that multiple is a modest premium to the current ~11.7x, justified by 70% gross margins, low beta, robust FCF, and an accelerating sales trajectory, while still being conservative versus ZBH's historical P/S and P/E ranges.